Unlocking the Potential of Antibody-Drug Conjugates

Abstract

One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.